I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am a Healthcare Professional outside the US and UK Read more
I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

I am not a Healthcare Professional and I am outside the US and the UK Read more
Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

Our Compounds

Our extensive oncology clinical trial programme has produced two approved drugs, as well as several other investigational compounds that are currently being investigated across a broad range of tumour types. Find out more below. 

Download a PDF of our compounds
Filter by:
Focus Area
Development stage
Compound Target Focus area Development stage
  • Phase I
  • Phase II
  • Phase III
  • Approved

Afatinib
NCE po (GIOTRIF®)

Discover more
  • EGFR (ErbB1); HER2 (ErbB2); ErbB3; ErbB4
  • Non-small cell lung cancer first line epidermal growth factor mutation-positive
  1. 1
  2. 2
  3. 3
  4. A
  • Squamous histology non-small cell carcinoma
  1. 1
  2. 2
  3. 3
  4. A
  • Head and neck squamous cell carcinoma
  1. 1
  2. 2
  3. 3
  4. A

Nintedanib
NCE po (VARGATEF®)

Discover more
  • VEGFR; FGFR; PDGFR
  • Non-small cell lung cancer second line
  1. 1
  2. 2
  3. 3
  4. A

Xentuzumab
NBE iv

Discover more
  • IGF1; IGF2
  • Breast cancer (Phase I/II)
  1. 1
  2. 2
  3. 3
  4. A
  • Castration-resistant prostate cancer (Phase I/II)
  1. 1
  2. 2
  3. 3
  4. A
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A
  • Non-small cell lung cancer
  1. 1
  2. 2
  3. 3
  4. A

CD33 monoclonal antibody
NBE iv

Discover more
  • CD33
  • Acute myeloid leukaemia
  1. 1
  2. 2
  3. 3
  4. A
  • Myelodysplastic syndrome
  1. 1
  2. 2
  3. 3
  4. A

VEGF/Ang2 inhibitor
NBE iv

Discover more
  • VEGF; Ang-2
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A

mRNA-based cancer vaccine
mRNA-based ICV (CV9202)

Discover more
  • NY-ESO-1; MAGE C1; MAGE C2; TPBG; Survivin; MUC1
  • Non-small cell lung cancer
  1. 1
  2. 2
  3. 3
  4. A

BET inhibitor
NCE po

Discover more
  • BET
  • Solid tumours - non-Hodgkin lymphoma
  1. 1
  2. 2
  3. 3
  4. A

PD-1 inhibitor
NBE iv

Discover more
  • PD-1
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A
Download a PDF of our compounds
Back to top

Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

Xentuzumab, BI 836858, BI 836880, BI 1361849, BI894999, BI 754091, BI 754111 and BI 891065 are investigational compounds and have not been approved. Their safety and efficacy have not been established.

 

Ang-2, angiopoietin-2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; iv, intravenous; LAG3, lymphocyte activation gene 3 protein; MAGE, melanoma-associated antigen; mRNA-based ICV, messenger ribonucleic acid-based immunotherapeutic cancer vaccine; MUC1, mucin 1, cell surface associated; NBE, new biological entity; NCE, new chemical entity; NY-ESO-1, New York esophageal squamous cell carcinoma 1; PD-1, programmed cell death protein 1; po, orally; PDGFR, platelet-derived growth factor receptor; SMAC, second mitochondria-derived activator of caspase; TPBG, trophoblast glycoprotein; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.